Skip to main content

3 Result(s)

within Jia-jie Shi Remove this filter

and

  1. No Access

    Article

    CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer

    The third-generation epidermal growth factor receptor (EGFR) inhibitor osimertinib (OSI) has been approved as the first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). This study aims to exp...

    Wei-Bang Yu, Yu-Chi Chen, Can-Yu Huang, Zi-Han Ye, Wei Shi… in Frontiers of Medicine (2023)

  2. No Access

    Article

    Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective

    CD47, a transmembrane protein, acts as a “do not eat me” signal that is overexpressed in many tumor cell types, thereby forming a signaling axis with its ligand signal regulatory protein alpha (SIRPα) and enab...

    Yu-Chi Chen, Wei Shi, Jia-Jie Shi… in Journal of Cancer Research and Clinical On… (2022)

  3. No Access

    Article

    The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8

    Tamoxifen, an important endocrine therapeutic agent, is widely used for the treatment of estrogen receptor positive (ER+) breast cancer. However, de novo or acquired resistance prevents patients from benefitting ...

    Jia-jie Shi, Si-meng Chen, Chen-liang Guo, Yi-xue Li… in Acta Pharmacologica Sinica (2018)